JUPITER NEUROSCIENCES INC. (JUNS)
$0.35
$0.01
(3.89%)
As on 14-May-2026 16:16EDT
Market cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
227.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
36,281,252
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
| -65.7 | -12.4 | -39.5 | -45.8 | -- | -- | -- |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
| -90.5 |
|
S&P Small-Cap 600
| 4.0 |
|
BSE Sensex
| 9.1 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
JUPITER NEUROSCIENCES INC (JUNS)
|
0.3 | 12.2 | 0.0 | -9.7 | -5,195.6 | -- | -- | 227.7 |
| 4.1 | 400.4 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.1 | |
| 19.8 | 1,205.0 | 0.0 | -167.9 | -- | -128.7 | -- | 5.6 | |
| 12.7 | 2,213.0 | 550.0 | 458.1 | -3.3 | 45.9 | 4.9 | 1.8 | |
| 5.6 | 1,204.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.1 | 1,875.9 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.3 | |
| 13.0 | 891.5 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.4 | 3.4 | |
| 3.1 | 585.2 | 3.2 | -198.4 | -4,800.7 | -166.3 | -- | 7.6 | |
| 18.0 | 424.8 | 4.7 | -109.7 | -- | -30.2 | -- | 1.3 | |
| 20.3 | 2,201.0 | 453.3 | -178.1 | -27.8 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout JUPITER NEUROSCIENCES INC (JUNS)
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in... two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida. Address: 1001 North US Highway 1, Jupiter, FL, United States, 33477 Read more
-
Co-Founder, CEO & Chairman of the Board
Mr. Christer Rosen
-
Co-Founder, CEO & Chairman of the Board
Mr. Christer Rosen
-
Headquarters
Jupiter, FL
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for JUPITER NEUROSCIENCES INC (JUNS)
What is the current share price of JUPITER NEUROSCIENCES INC (JUNS) Today?
The share price of JUPITER NEUROSCIENCES INC (JUNS) is $0.35 (NASDAQ) as of 14-May-2026 16:16 EDT. JUPITER NEUROSCIENCES INC (JUNS) has given a return of -45.81% in the last 1 years.
What is the current PB & PE ratio of JUPITER NEUROSCIENCES INC (JUNS)?
Since, TTM earnings of JUPITER NEUROSCIENCES INC (JUNS) is negative, P/E ratio is not available.
The P/B ratio of JUPITER NEUROSCIENCES INC (JUNS) is 227.66 times as on 12-May-2026, a 4329 premium to its peers’ median range of 5.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.13
|
-19.49
|
|
2024
|
-127.19
|
74.38
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
What is the 52 Week High and Low of JUPITER NEUROSCIENCES INC (JUNS)?
The 52-week high and low of JUPITER NEUROSCIENCES INC (JUNS) are Rs 3.33 and Rs 0.31 as of 15-May-2026.
What is the market cap of JUPITER NEUROSCIENCES INC (JUNS)?
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalisation of $ 12 Mln as on 12-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in JUPITER NEUROSCIENCES INC (JUNS)?
Before investing in JUPITER NEUROSCIENCES INC (JUNS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.